Intra-Cellular Therapies Patent-Cliff Exposure & CMS Drug Spending Portfolio

Intra-Cellular Therapies (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $595.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2040-01-01
2024 CMS Total Public Spend$595.9M
2024 Medicare Part D Spend$268.5M
2024 Medicaid Spend$327.4M
California HCAI SB 17 Filings2 WAC filings (max 18.9% 2-yr change)